VEGFA and cancer: The employed 3D metabolomics by LC/MS and NMR spectroscopy revealed the mechanism-specific inhibitory profiles of amifostine (a clinically used drug with a radioprotective and cytoprotective properties to normal tissues in patients subjected to anti-cancer therapies) against vascular endothelial growth factor A (VEGF-A) and deferoxamine-induced angiogenesis.